Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
CEL-SCI Corporation is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases, notably its lead product, Multikine, which is in late-stage clinical trials for head and neck cancer. The company's unique competitive advantage lies in its proprietary technology platform that enhances the immune response, potentially offering a differentiated treatment option in a crowded oncology market.
CEL-SCI primarily relies on funding from grants and partnerships to support its clinical development of Multikine. The company aims to monetize its product through eventual sales, contingent on successful trial outcomes. Its competitive advantage stems from a unique approach to immunotherapy that targets the immune system's response, which may lead to better patient outcomes compared to existing therapies.
Results from clinical trials for Multikine, particularly Phase III outcomes
Regulatory approvals from the FDA or other health authorities
Partnership announcements or funding agreements
Market sentiment towards biotechnology stocks
Regulatory changes that could impact drug approval processes
Technological disruption from new cancer therapies or treatment modalities
Emerging immunotherapy competitors with similar or superior efficacy
Potential for larger pharmaceutical companies to dominate the oncology market
High negative cash flow impacting liquidity and operational sustainability
Debt levels that could constrain future financing options
low - The biotechnology sector is generally less sensitive to economic cycles, as healthcare spending tends to be more stable.
Moderate - Rising interest rates could increase the cost of capital for funding clinical trials, impacting the company's ability to finance operations.
minimal - The company has a manageable debt level, but its reliance on equity financing and grants reduces credit dependency.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
high - The stock has exhibited significant volatility, particularly in response to clinical trial results and funding news.